← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
ceftazidime and beta-lactamase inhibitor
J01DD52
Forms & Strengths
- 1g ceftazidime/0.5g avibactam
- 2g ceftazidime/1g avibactam
- Powder for injection
Adult Dosing
- 2g ceftazidime/1g avibactam IV q8h
- For cUTI, dosing is 1g ceftazidime/0.5g avibactam IV q8h
- For HAP/VAP, dosing is 2g ceftazidime/1g avibactam IV q8h
Pediatric Dosing
- For pediatric patients (≥3 months to <18 years): 2g ceftazidime/1g avibactam IV q8h
- For pediatric patients (≥3 months to <18 years) with cUTI: 1g ceftazidime/0.5g avibactam IV q8h
Indications
- Complicated urinary tract infections (cUTI)
- Hospital-acquired pneumonia (HAP)
- Ventilator-associated pneumonia (VAP)
Mechanism of Action
- Ceftazidime is a cephalosporin antibiotic, inhibiting cell wall synthesis
- Avibactam is a beta-lactamase inhibitor, preventing antibiotic degradation
Contraindications
- Known severe hypersensitivity to ceftazidime, avibactam, or other cephalosporins
- Known hypersensitivity to penicillins or other beta-lactams
Adverse Reactions
- Hypersensitivity reactions
- GI disturbances (e.g., diarrhea, nausea, vomiting)
- Nephrotoxicity
- Candidiasis
Drug Interactions
- Concomitant use with nephrotoxic agents may increase risk of nephrotoxicity
- Coadministration with probenecid may increase ceftazidime concentrations
Curated Content: Needs Vetting Before Put to Clinical Use